Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Cardax, Inc. logo — Cardax is developing orally bioavailable anti-inflammatory c...

Cardax, Inc.

Cardax is developing orally bioavailable anti-inflammatory compounds with robust safety for major unmet medical needs.

Founded 2006 United States Honolulu, United States 17 employees Post-IPO Equity Biopharma, Biotechnology +2

General Information

Company Name Cardax, Inc.
Founded Year 2006
Location United States Honolulu, United States
Founders / Decision Makers
Team member Team member
Employees 17
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Cardax, Inc.. To contact Cardax, Inc., visit cardaxpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cardax, Inc. compare?

A PDF of Cardax, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cardax, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cardax, Inc.

Cardax, Inc. is a US-based company, founded in 2006, specializing in the development of orally bioavailable anti-inflammatory compounds to address major unmet medical needs. The company focuses on creating proprietary astaxanthin therapies for conditions in which oxidative stress and inflammation play significant roles. Cardax's products aim to provide the anti-inflammatory benefits of steroids or NSAIDS, with an emphasis on safety, as confirmed by the U.S. Food and Drug Administration's Generally Recognized as Safe (GRAS) designation. The company is dedicated to developing nutraceutical and pharmaceutical products for various diseases, including osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The company's flagship focus lies in its astaxanthin technologies, a naturally occurring anti-inflammatory and antioxidant with a strong safety profile. Unlike traditional anti-inflammatory treatments, astaxanthin offers powerful benefits without adverse side effects such as immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding. Cardax received a Post-IPO Equity investment on 28 April 2017. The investment details and investors remain undisclosed. As an emerging player in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industry, Cardax, Inc. is well-positioned to potentially revolutionize the treatment landscape for various medical conditions by leveraging the power of natural compounds in a safe and effective manner.

Business keywords: Life Sciences, Pharmaceuticals, Nutraceuticals, Anti-inflammatory Compounds, Oxidative Stress, Astaxanthin Therapies, Metabolic Disease, Cardiovascular Disease, Rheumatoid Arthritis, Dyslipidemia, Osteoarthritis, Cognitive Decline, Macular Degeneration, Prostate Disease, Small Molecule Therapies

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
28 Apr 2017
Post IPO Equity Undisclosed -
20 May 2016
Post IPO Equity Undisclosed -
17 Nov 2015
Venture Series Unknown Undisclosed -
30 Jun 2015
Debt Financing Undisclosed -
17 Jan 2014
Debt Financing Undisclosed -
17 Jun 2013
Debt Financing Undisclosed -
27 Sep 2010
Venture Series Unknown Undisclosed -
23 Dec 2008
Venture Series Unknown Undisclosed -
31 Mar 2004

Cardax, Inc. Alternatives & Competitors

View All Alternatives
Cardax, Inc. vs
Arctic Bioscience
Arctic Bioscience Norway

Norwegian membrane lipid extracts

Post-IPO Debt
45 employees
Biopharma, Biotechnology
Cardax, Inc. vs
Causaly
Causaly United Kingdom

Unlock R&D productivity with the most complete AI platform for life sciences.

Series B
119 employees
Biotechnology, Pharmaceutical
Cardax, Inc. vs
DSM
DSM The Netherlands

inactive - follow dsm-firmenich

IPO
12087 employees
Biotechnology, Health Care
View all alternatives

FAQ About Cardax, Inc.

Cardax is developing orally bioavailable anti-inflammatory compounds with robust safety for major unmet medical needs.
Cardax, Inc. was founded in 2006.
Cardax, Inc. is headquartered in Honolulu, United States.
Cardax, Inc. operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Life Sciences, Pharmaceuticals, Nutraceuticals and Anti-inflammatory Compounds.
Cardax, Inc. has approximately 17 employees.
Cardax, Inc. has completed 9 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Cardax, Inc. include Arctic Bioscience, Causaly, DSM, Gangwal Healthcare Private Limited, Nawah Scientific. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cardax, Inc. and Arctic Bioscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cardax, Inc., https://bouncewatch.com/company/cardax-inc, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes